Report library

Actemra

Actemra (tocilizumab; Roche/Chugai), known as RoActemra in Europe, is a first-in-class humanized interleukin-6 receptor monoclonal antibody.

March 24, 2015

Pacts in Medtech

$199.00

Pacts in Medtech – September/October 2016 – notable technology alliances, R&D partnerships and commercial collaborations disclosed in July and August 2016.

November 18, 2016

France Regulatory Issues

$2,995.00

The much-criticized delay in the removal of marketing authorization for Servier’s Mediator in France has had profound implications for reform of the country’s regulatory system.

November 2, 2016

GLP-1 Pulse Survey

This survey of US primary care physicians (n=10) and endocrinologists (n=10) was undertaken to evaluate the impact of GLP-1 agonists if they were to be introduced in the Diabetes market.

August 25, 2014

Datamonitor Meningococcal Vaccines KOL Interview

Datamonitor interviewed an infectious diseases specialist based in the US Greater Washington DC area to determine this physician’s views on marketed and pipeline meningococcal vaccines.

July 12, 2016

2015 PCSK9 Inhibitors Pulse

Following the approval of the first PCSK9 Inhibitor, Praluent (SNY, REGN), this 5- question survey of 23 cardiologists evaluated attitudes towards the class, projected usage prior to their CVOTs depending on insurance prior authorization, preference of Praluent vs Repatha (AMGN), and how the oral CETP inhibitors would impact PCSK9 usage under different outcomes study scenarios.

August 19, 2015

Brintellix

Brintellix (vortioxetine; Lundbeck/Takeda) is the latest antidepressant to be approved in the US for major depressive disorder. The drug follows a successful line of antidepressants developed by Lundbeck, which includes Cipralex (escitalopram) and Cipramil (citalopram).

May 5, 2016

Contract Research Organizations: Health and Wealth in 2013

$5,000.00

For public contract research organizations (CROs), the financial story in 2013 was one of solid and steady growth. Revenues grew and company-estimated forecasts for 2014 are also positive.

November 3, 2016

Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – France

This interview with a French key opinion leader (KOL) provides insight into pipeline therapies for non-alcoholic steatohepatitis (NASH), as well as pricing strategies and future treatment rates for the different fibrosis stages of NASH.

May 20, 2019

Reasanz

Reasanz (serelaxin; Novartis) has not yet obtained approval in the US, Japan, or EU for the treatment

of acute decompensated heart failure (ADHF), despite its fast track and breakthrough therapy

designations from the US Food and Drug Administration (FDA).

March 16, 2016

Datamonitor Schizophrenia KOL Interview

On key factors effecting treatment: “First of all tolerability, because if the tolerability is not good then there will be no adherence. The second is efficacy, and the third one maybe is also whether the compound is also available as a depot. I think that is a major advantage if a drug, if an antipsychotic, is indeed available as a depot or as a long-acting injection (LAI).”

February 10, 2016

Surgical Heart Valve Repair and Replacement Devices

$4,750.00

This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the surgical heart valve repair (annuloplasty) systems and surgical heart valve replacement products markets for the US, 5 Euro (France, Germany, Italy, Spain, and UK), Japan, and Rest of World markets from 2020–25.

June 28, 2021

Squalamine

Ohr Pharmaceutical will aim to make squalamine (OHR-102) the first topical treatment approved for

wet age-related macular degeneration (AMD)

September 8, 2017

Coumadin

Coumadin is an orally available vitamin K antagonist (VKA) indicated for the prophylaxis and

treatment of deep vein thrombosis and pulmonary embolism.

August 2, 2016

Datamonitor Psoriatic Arthritis KOL Interviews

Datamonitor interviewed three rheumatologists, two based in the US and one in the UK, to determine their current treatment practices and views on pipeline and marketed drugs for psoriatic arthritis. The three interviews were combined into a single report.

December 12, 2016

Market Spotlight: Coronary Artery Disease

This Market Spotlight report covers the Coronary Artery Disease (CAD) market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, probability of success, and 10-year disease prevalence and incidence forecasts, as well as presenting drug-specific revenue forecasts.

July 27, 2022

Ofatumumab

Ofatumumab (Genmab/Novartis) is a fully human immunoglobulin G1 and high-affinity antibody that targets a novel epitope on cluster of differentiation (CD)20 on the B-cell membrane. Ofatumumab binds effectively to both the small and large extracellular loops on CD20 and releases very slowly over time.

November 24, 2017

Lovenox

Lovenox (enoxaparin; Sanofi/Kaken Pharmaceutical) is a subcutaneous low molecular weight heparin approved for the prophylaxis of deep vein thrombosis (DVT)…

August 2, 2016

Tezacaftor/Ivacaftor

Vertex’s tezacaftor (formerly known as VX-661) is a CFTR corrector compound being investigated as an adjunct to Vertex’s other marketed and developmental CFTR-targeting products. The drug’s initial development is as part of a fixed-dose combination with the CFTR potentiator ivacaftor (Vertex), which was approved with the brand name Kalydeco in January 2012.

September 14, 2017

Market Spotlight: Thyroid Eye Disease (TED)

Thyroid eye disease (TED), also called Graves’ ophthalmopathy or orbitopathy, is an autoimmune disorder that causes inflammation in the orbital and retroocular tissues. It generally occurs as a manifestation of Graves’ disease, a condition in which the immune system attacks the thyroid gland, commonly affecting the eyes and skin. Although TED is usually found in Graves’ hyperthyroidism patients, some patients may have autoimmune euthyroid or hypothyroid thyroiditis. TED is mostly a mild, non-progressive, and self-limiting disease; however, in rare cases it can progress to vision loss. The negative impact of TED on the social and psychological well-being of individuals is an established consequence of the disease.

June 3, 2022

Synagis

Synagis (palivizumab; AstraZeneca/AbbVie) is the global standard of care for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease.

October 5, 2018

Acute Myeloid Leukemia (AML) KOL Interview – US, South

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include idasanutlin, oral azacitidine, and pevonedistat.

March 14, 2022

RSV preF vaccine

Pfizer’s RSV preF vaccine is based on the prefusion form of the RSV fusion protein, aided by the discovery of the crystal structure of key viral proteins by the National Institutes of Health.

October 5, 2018

Breo Ellipta

Breo Ellipta (GlaxoSmithKline/Innoviva) is a combination of fluticasone furoate and vilanterol indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

July 31, 2018

Market Spotlight: Mantle Cell Lymphoma

This Market Spotlight report covers the Mantle Cell Lymphoma (MCL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

April 7, 2022

Thalomid

Thalomid contains thalidomide, a glutamic acid derivative that possesses immunomodulatory, antiinflammatory,
and anti-angiogenic properties.

August 9, 2018

Disease Analysis: HIV Treatment

The HIV treatment market in the US, Japan, and five major European markets (France, Germany, Italy, Spain, and the UK) is expected to continue to expand through to 2025, driven primarily by increases in disease prevalence and continued uptake of Gilead’s Biktarvy and ViiV Healthcare’s portfolio of two-drug regimens. However, a plethora of products undergoing patent expiry across the forecast period will tip the market into decline from 2026.

February 4, 2022

Market Spotlight: Sickle Cell Anemia

This Market Spotlight report covers the Sickle Cell Anemia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals.

June 9, 2022

Zejula

Zejula (niraprib; Tesaro/Takeda) is a small molecule inhibitor of poly (ADP-ribose) polymerase (PARP). PARP inhibitors block the activity of PARP, an enzyme that plays an essential role in DNA repair mechanisms and homologous recombination events by directly blocking enzymatic activity, or by causing PARP to accumulate on DNA (PARP trapping), which results in DNA replication inhibition and cell death.

August 17, 2017

Diabetes Management: Insulin Pumps Market (2019)

$4,750.00

This report provides an overview of diabetes, automated insulin pump systems, and a comprehensive market and competitive analysis.

September 30, 2019

PF-06482077

Pfizer’s PF-06482077 is a 20-valent pneumococcal conjugate vaccine, which is currently in Phase II development in the US and EU. PF-06482077 contains the 13 serotypes included in Prevnar 13 (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A), as well as seven additional serotypes.

December 21, 2018

Invanz

Invanz (ertapenem; Merck & Co) is a carbapenem antibacterial agent that inhibits bacterial cell wall synthesis through binding to penicillin-binding proteins. The drug inhibits the crosslinking of…

June 19, 2015

Cabometyx

Cabometyx (cabozantinib; Exelixis/Ipsen/Takeda) is an orally available small molecule inhibitor which has been shown to suppress tumor growth and metastasis by inhibiting the activity of multiple tyrosine kinases including MET, AXL, and vascular endothelial growth factor receptor (VEGFR).

September 9, 2019

Trintellix

Trintellix (vortioxetine; Lundbeck/Takeda) is the latest antidepressant to be approved in the US for major depressive disorder (MDD). The drug follows a successful line of antidepressants developed by Lundbeck, which includes Cipralex (escitalopram) and Cipramil (citalopram). Trintellix was first approved in the US in September 2013 and was made commercially available in January 2014, under the brand name Brintellix.

March 29, 2019

Zulresso

Zulresso is SAGE Therapeutics’ proprietary intravenous formulation of brexanolone, which is an allosteric modulator of both synaptic and extra-synaptic GABA-A receptors.

March 29, 2019

cabotegravir/rilpivirine

Cabotegravir is an integrase strand transfer inhibitor analog of Tivicay (dolutegravir; ViiV Healthcare), and rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), branded as Edurant (Johnson & Johnson).

June 28, 2019

Seroquel/Seroquel XR

The Seroquel franchise contains quetiapine, which acts as an antagonist at multiple neurotransmitter receptors in the brain, such as serotonin 5-HT1A and 5-HT2, dopamine D1 and D2, histamine H1, and adrenergic alpha 1 and alpha 2 receptors.

March 29, 2019

Pain Management Devices Market

$4,750.00

This comprehensive medical market and technology report provides an overview of the medical devices (eg, electrical stimulators and analgesia infusion pumps) used in the management of chronic pain, and includes an in-depth market analysis. This global report covers the US, European, and Rest of World (RoW) markets.

The report provides the following useful information:

pain management overview
key statistics on pain prevalence in major world regions
medical device product portfolios offered by leading manufacturers
top selling products, as well as emerging products under development
in-depth market and competitive analyses

Medical devices covered in this report include:

electrical nerve stimulators (transcutaneous electrical nerve stimulators [TENS] and neurostimulation products including spinal cord stimulators [SCSs], discussed in Chapter 2)
analgesia infusion pumps and accessories (implantable analgesia infusion pumps and external analgesia infusion pumps, discussed in Chapter 3)

June 1, 2017

Prostate Cancer KOL Interview – US, Northeast #2

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Key pipeline assets highlighted include Keytruda, Tecentriq, Opdivo, ipatasertib, capivasertib, Lutetium 177Lu-PSMA-617, and CAN-2409.

February 9, 2022

Geodon

Geodon contains ziprasidone, a dopamine (D2) and serotonin (5-HT2) antagonist developed and marketed by Pfizer.

April 9, 2018

Disease Analysis: Schizophrenia

The current dynamics of the antipsychotic market show domination by atypical antipsychotics, mainly oral agents, but there is also increasing uptake of long-acting injectable (LAI) neuroleptics, which will continue. Oral atypical antipsychotics that were historical blockbusters are now facing intense generic erosion. The highest-selling oral antipsychotic is Latuda, one of the newer atypical drugs, but its market exclusivity is only set to last until 2023.

March 30, 2022

APL-130277

APL-130277 (Dainippon Sumitomo/Sunovion) is a sublingual film formulation of apomorphine, a non-ergoline dopamine receptor agonist.

June 21, 2018

Market Spotlight: Sjögren’s Syndrome

This Market Spotlight report covers the Sjögren’s syndrome market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals.

July 26, 2022

5EU Surgical Procedure Volumes: Cardiovascular and Peripheral Vascular Procedures

$3,000.00

This report presents procedure volumes forecasts for some of the most common cardiovascular and peripheral vascular surgical procedures performed in the five EU countries of France, Germany, Italy, Spain, and the UK (5EU). The forecast period covered by this report is for the years 2016 through 2021.

December 6, 2017